GlassScriptPhysician profile
Haris Ali Baig
NPI 1699919456
$8,766.31
in general payments reported to CMS, 2019-2025
64 companies · $2,801 in 2025
The $2,801 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.84 · 2020: $45.48 · 2021: $11.92 · 2022: $815 · 2023: $1,892 · 2024: $3,123 · 2025: $2,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,640 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,640.30 |
| Education | $176.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $901.33 | 2022-2025 | |
| Celgene Corporation | $644.84 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $584.74 | 2022-2025 | |
| Janssen Biotech, INC. | $559.08 | 2022-2025 | Rybrevant, Tecvayli, Talvey |
| Astellas Pharma US INC | $436.68 | 2022-2025 | Vyloy, Xtandi, Padcev |
| Astrazeneca Pharmaceuticals LP | $379.36 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| Eisai INC. | $378.09 | 2020-2025 | |
| Springworks Therapeutics, INC. | $346.00 | 2024-2025 | Ogsiveo, Gomekli |
| E.R. Squibb & Sons, L.L.C. | $303.22 | 2022-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $296.72 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Genzyme Corporation | $284.80 | 2019-2025 | |
| Sobi, INC | $262.27 | 2024-2025 | |
| Tempus Ai, INC | $234.56 | 2024-2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $187.84 | 2022-2024 | Clonoseq |
| Abbvie INC. | $155.68 | 2023-2025 | Venclexta |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $154.11 | 2023-2024 | Alecensa, Tecentriq, Rozlytrek |
| Tersera Therapeutics LLC | $153.92 | 2024-2025 | Zoladex, Xermelo, Quzyttir |
| Beigene USA, INC. | $145.81 | 2023-2024 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $142.35 | 2023-2025 | Monoferric |
| Glaxosmithkline, LLC. | $132.54 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Rigel Pharmaceuticals, INC. | $123.46 | 2022-2024 | Tavalisse, Rezlidhia |
| Stemline Therapeutics INC. | $123.24 | 2023-2025 | Orserdu |
| Array Biopharma INC | $118.05 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmaessentia USA Corporation | $105.22 | 2024-2025 | Besremi |
| Gilead Sciences, INC. | $98.60 | 2021-2024 | Trodelvy |
| Kite Pharma, INC. | $94.82 | 2025 | Yescarta |
| Fennec Pharmaceuticals, INC. | $87.79 | 2023-2024 | Pedmark |
| Aveo Pharmaceuticals, INC. | $83.71 | 2022-2025 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $78.48 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $76.11 | 2023-2024 | Qinlock |
| Amgen INC. | $75.76 | 2022-2023 | Kyprolis, Blincyto |
| Tactile Systems Technology INC | $73.21 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Seagen INC. | $69.99 | 2022 | |
| Karyopharm Therapeutics INC. | $64.39 | 2020-2024 | Xpovio |
| Immunocore Limited | $55.11 | 2025 | Kimmtrak |
| Incyte Corporation | $50.94 | 2024-2025 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $50.82 | 2024-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $46.70 | 2024-2025 | Ninlaro, Fruzaqla |
| Jazz Pharmaceuticals INC. | $40.02 | 2024-2025 | |
| Boston Scientific Corporation | $37.64 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Agios Pharmaceuticals, INC. | $36.87 | 2025 | Pyrukynd |
| Merck Sharp & Dohme LLC | $33.76 | 2024-2025 | Keytruda, Welireg |
| Amneal Pharmaceuticals LLC | $32.96 | 2023-2025 | Alymsys, Neupogen, Avastin |
| Apellis Pharmaceuticals, INC. | $32.56 | 2024 | Empaveli |
| Myovant Sciences INC. | $28.45 | 2022 | |
| Cti Biopharma Corp. | $25.77 | 2022 | |
| Alexion Pharmaceuticals, INC. | $25.15 | 2023 | Ultomiris |
| Blueprint Medicines Corporation | $24.06 | 2023 | Ayvakit |
| Inari Medical, INC. | $23.42 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Menarini Silicon Biosystems, INC. | $23.31 | 2024 | |
| Kyowa Kirin, INC. | $22.60 | 2025 | |
| Taiho Oncology, INC. | $22.17 | 2023 | |
| Genmab U.S., INC. | $21.24 | 2024 | Tivdak |
| Caris Mpi, INC. | $20.27 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $19.75 | 2024 | |
| Sirtex Medical INC | $19.17 | 2024 | Sir-Spheres Microspheres |
| Sun Pharmaceutical Industries INC. | $18.70 | 2023 | Odomzo, Yonsa |
| Adc Therapeutics America, INC. | $17.93 | 2023 | |
| Myriad Genetic Laboratories, INC. | $17.77 | 2023 | Myrisk |
| Legend Biotech USA INC. | $17.06 | 2024 | |
| Mirati Therapeutics, INC. | $16.62 | 2024 | Krazati |
| Beone Medicines USA, INC. | $14.74 | 2025 | Tevimbra |
| Janssen Pharmaceuticals, INC | $13.98 | 2023 | Xarelto |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haris Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.